Rivaroxaban in Peripheral Artery Disease after Revascularization | Zendy

Marc P. Bonaca | Zendy; Rupert Bauersachs | Zendy; Sonia S. Anand | Zendy; E. Sebastian Debus | Zendy; Mark R. Nehler | Zendy; Manesh R. Patel | Zendy; Fabrizio Fanelli | Zendy; Warren H. Capell | Zendy; Lihong Diao | Zendy; Nicole Jaeger | Zendy; Connie N. Hess | Zendy; Ákos F. Pap | Zendy; John M. Kittelson | Zendy; Ivan Gudz | Zendy; Lajos Mátyás | Zendy; Dainis Krieviņš | Zendy; Rafael Díaz | Zendy; Marianne Brodmann | Zendy; Eva Muehlhofer | Zendy; Lloyd Haskell | Zendy; Scott D. Berkowitz | Zendy; William R. Hiatt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rivaroxaban in Peripheral Artery Disease after Revascularization

Author(s) -

Marc P. Bonaca,

Rupert Bauersachs,

Sonia S. Anand,

E. Sebastian Debus,

Mark R. Nehler,

Manesh R. Patel,

Fabrizio Fanelli,

Warren H. Capell,

Lihong Diao,

Nicole Jaeger,

Connie N. Hess,

Ákos F. Pap,

John M. Kittelson,

Ivan Gudz,

Lajos Mátyás,

Dainis Krieviņš,

Rafael Díaz,

Marianne Brodmann,

Eva Muehlhofer,

Lloyd Haskell,

Scott D. Berkowitz,

William R. Hiatt

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2000052

Subject(s) - rivaroxaban , arterial disease , revascularization , medicine , peripheral , cardiology , disease , vascular disease , warfarin , myocardial infarction , atrial fibrillation

Patients with peripheral artery disease who have undergone lower-extremity revascularization are at high risk for major adverse limb and cardiovascular events. The efficacy and safety of rivaroxaban in this context are uncertain.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research